Piperazines

"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

No definition found.

Descriptor ID	D010879
MeSH Number(s)	D03.383.606
Concept/Terms	Piperazines Piperazines

Below are MeSH descriptors whose meaning is more general than "Piperazines".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Piperazines [D03.383.606]

Below are MeSH descriptors whose meaning is related to "Piperazines".

Below are MeSH descriptors whose meaning is more specific than "Piperazines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.

Bar chart showing 36 publications over 19 distinct years, with a maximum of 3 publications in 2005 and 2006 and 2009 and 2018 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	1	1
1994	1	0	1
2002	2	0	2
2003	1	0	1
2005	2	1	3
2006	2	1	3
2007	1	0	1
2008	0	1	1
2009	2	1	3
2010	1	1	2
2012	1	0	1
2013	1	1	2
2014	2	0	2
2015	1	1	2
2016	2	0	2
2017	1	0	1
2018	2	1	3
2019	2	1	3
2020	1	1	2

Below are the most recent publications written about "Piperazines" by people in Profiles.

Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497.

View in: PubMed
Tripathi A, Balakrishna P, Agarwal N. PARP inhibitors in castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100199.

View in: PubMed
Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer. Future Oncol. 2019 Oct; 15(30):3435-3449.

View in: PubMed
Lee KA, Shepherd ST, Johnston SR. Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol. 2019 Oct; 15(29):3309-3326.

View in: PubMed
Washington C, Gunderson CC, Moore KN. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. Curr Opin Obstet Gynecol. 2019 02; 31(1):4-11.

View in: PubMed
De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.

View in: PubMed
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505.

View in: PubMed
Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.

View in: PubMed
Dockery LE, Tew WP, Ding K, Moore KN. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513.

View in: PubMed
Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE. A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence. Oncotarget. 2016 Nov 08; 7(45):72443-72457.

View in: PubMed

People

Explore

Similar Concepts

Top Journals